The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
Panelli
Monica C
MC
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland, USA.
Wang
Ena
E
Marincola
Francesco M
FM
D000951:Antigens, Neoplasm / Q000235:genetics* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000235:genetics* / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology*; D018579:Patient Selection; D011379:Prognosis; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007376:Interleukin-2; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases